Just caught RVMD absolutely ripping today while everything else is getting hammered. Stock jumped to $131 and change, up over 35% on news that their pancreatic cancer drug cut death risk by 60% in Phase 3 trials. This is the kind of biotech stocks move that makes you wonder if you missed the setup. Leerink and Guggenheim both raised price targets significantly, which definitely helped fuel the rally. Up 67% for the year already, and this is tracking as the best single day on record for the company. What's interesting is the short squeeze potential sitting underneath this. Short interest has been climbing, now at 7.6% of float, and at normal trading volume it would take shorts nearly a full week to unwind. That could keep buying pressure going. Plus options traders have been loaded up on bearish bets the last couple weeks, but today the skew completely flipped to calls. Call volume is running 12x average, which tells you retail is jumping in. For biotech stocks like this, when you get clinical wins combined with short covering and options activity all lining up, that's when you get these kinds of explosive moves. Still watching to see if this holds or if we're looking at a pullback into earnings.